Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38αMAPK Inhibitor That Attenuates Disease Progression in Alzheimer’s Disease Mouse Models

[Image: see text] The first kinase inhibitor drug approval in 2001 initiated a remarkable decade of tyrosine kinase inhibitor drugs for oncology indications, but a void exists for serine/threonine protein kinase inhibitor drugs and central nervous system indications. Stress kinases are of special in...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Saktimayee M., Grum-Tokars, Valerie L., Schavocky, James P., Saeed, Faisal, Staniszewski, Agnieszka, Teich, Andrew F., Arancio, Ottavio, Bachstetter, Adam D., Webster, Scott J., Van Eldik, Linda J., Minasov, George, Anderson, Wayne F., Pelletier, Jeffrey C., Watterson, D. Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2015
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404319/
https://www.ncbi.nlm.nih.gov/pubmed/25676389
http://dx.doi.org/10.1021/acschemneuro.5b00002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404319/
https://www.ncbi.nlm.nih.gov/pubmed/25676389
http://dx.doi.org/10.1021/acschemneuro.5b00002

Ejemplares similares